Christopher Paul German - 04 Mar 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Corporate Controller & CAO
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German
Issuer symbol
RYTM
Transactions as of
04 Mar 2026
Net transactions value
-$502,790
Form type
4
Filing time
06 Mar 2026, 16:51:07 UTC
Previous filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
German Christopher Paul Corporate Controller & CAO 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German 06 Mar 2026 0001260835

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +1,500 +35% $17.97* 5,753 04 Mar 2026 Direct
transaction RYTM Common Stock Sale $502,790 -5,614 -97% $89.56 160 04 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Options (Right to Buy) Options Exercise -1,500 -29% $0.000000* 3,731 04 Mar 2026 Common Stock 1,500 $17.97 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 21 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
F2 The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.